Hims & Hers Health (NYSE:HIMS) Now Covered by Analysts at Evercore ISI

Analysts at Evercore ISI started coverage on shares of Hims & Hers Health (NYSE:HIMS) in a research note issued to investors on Monday, MarketBeat.com reports. The firm set an “in-line” rating and a $33.00 price target on the stock. Evercore ISI’s target price suggests a potential upside of 4.14% from the company’s current price.

A number of other research firms have also recently weighed in on HIMS. KeyCorp started coverage on shares of Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. Bank of America upped their price objective on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research note on Tuesday, November 4th. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $44.54.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $31.69 on Monday. The firm has a market capitalization of $7.21 billion, a price-to-earnings ratio of 58.68, a PEG ratio of 5.37 and a beta of 2.37. Hims & Hers Health has a one year low of $23.97 and a one year high of $72.98. The business has a fifty day simple moving average of $36.88 and a 200 day simple moving average of $46.25. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same quarter in the prior year, the firm earned $0.32 EPS. The firm’s quarterly revenue was up 49.2% on a year-over-year basis. Sell-side analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health declared that its Board of Directors has approved a stock repurchase program on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 9,070 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $33.79, for a total value of $306,475.30. Following the transaction, the chief financial officer owned 91,617 shares of the company’s stock, valued at approximately $3,095,738.43. The trade was a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the sale, the insider owned 6,175 shares in the company, valued at $226,684.25. The trade was a 53.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 137,136 shares of company stock worth $5,283,072 over the last 90 days. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 4.5% in the third quarter. Vanguard Group Inc. now owns 19,518,015 shares of the company’s stock valued at $1,107,062,000 after acquiring an additional 844,991 shares during the last quarter. Capital World Investors raised its position in shares of Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after acquiring an additional 223,892 shares during the last quarter. Farallon Capital Management LLC lifted its stake in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. State Street Corp boosted its position in shares of Hims & Hers Health by 1.9% in the 3rd quarter. State Street Corp now owns 7,173,214 shares of the company’s stock worth $406,865,000 after purchasing an additional 132,384 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Hims & Hers Health by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock worth $236,622,000 after purchasing an additional 71,593 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.